Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ATCH vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATCH Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
ATCH Overall Winner
6-Pillar Tally: ATCH 4 – 1 ATYR (1 Tie)
Matrix Metrics: ATCH 6 – 2 ATYR
As of Nov 17, 2026, AtlasClear Holdings, Inc. (ATCH) is the stronger overall head-to-head candidate over aTyr Pharma, Inc. (ATYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ATCH carries a Unified Composite Score of 43.4/100 (HOLD) at $0.08 (N/M Forward P/E, -39.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: ATCH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ATCH vs ATYR
ATCH
Head-to-Head Winner
AtlasClear Holdings, Inc.
$0.08
-37.17% 1D
Market Cap
$20.1M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.59β · 136% Vol
Unified Composite Score
43.4
HOLD
Tech 25.0
Fund 48.0
Flow 50.0
Mom 63.9
Weinstein Technical Phase
Markdown · Sell / avoid
ATYR
aTyr Pharma, Inc. Common Stock
$4.96
-5.34% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.67β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ATCH 4 – 1 ATYR)
1. Valuation Multiples
ATCH
Forward P/E
N/M
N/M
Trailing P/E
6.6x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.6x
N/M
2. Growth & Scale
ATCH
Revenue Growth (YoY)
+136.8%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31M
N/A
Market Cap
$20.1M
$15.6M
3. Profitability & Quality
ATCH
Gross Margin
71.7%
N/A
Operating Margin
-39.4%
0.0%
Net Profit Margin
9.8%
0.0%
Return on Equity (ROE)
27.4%
-93.7%
4. Balance Sheet & Cash Flow
ATCH
Cash Generation (TTM)
-$4.8M EBITDA
N/A
Cash Flow Margin
-15.5% EBITDA Mgn
N/A
Net Cash / Leverage
$2.3M Net Cash
$4.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ATYR
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
154.5% (36th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Capital Markets Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ATCH (6) vs ATYR (2)| Institutional Metric | ATCH | ATYR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $20.1M | $15.6M | Tie | |
| Trailing P/E Ratio | 6.6x | N/M | ATCH | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +136.8% | +0.0% | ATCH | |
| Operating Margin (TTM) | -39.4% | 0.0% | ATYR | |
| Net Profit Margin | 9.8% | 0.0% | ATCH | |
| Return on Equity (ROE) | 27.4% | -93.7% | ATCH | |
| 52-Week Range Position | 4% ($0–$0) | 62% ($0–$8) | ATYR | |
| Beta / 30D Volatility | 1.59β · 136% Vol | -9.67β · 13806% Vol | ATCH | |
| Unified Institutional Score | 43.4 / 100 (HOLD) | 34.3 / 100 (SELL) | ATCH | |
| Trailing 12M Revenue (USD) | $31M | N/A | Scale | |
| Gross Profit Margin (TTM) | 71.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$4.8M EBITDA ($2.3M Net Cash) | N/A ($4.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +3469.31 pp
3M Horizon
ATYR +1355.95 pp
6M Horizon
ATYR +1393.2 pp
1Y Horizon
ATYR +976.77 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATCH Revenue | ATYR Revenue | ATCH Op. Margin | ATYR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -5445.0% | ATYR |
| FY2020 | N/A | $10M | N/A | -152.2% | ATYR |
| FY2022 | N/A | $10M | N/A | -446.8% | ATYR |
| FY2023 | N/A | $0M | N/A | -15557.8% | ATYR |
| FY2024 | N/A | $0M | N/A | -28899.6% | ATYR |
| FY2025 | $10M | $0M | -45.3% | -40856.3% | ATCH |
| FY2026 | $20M | N/A | -48.7% | N/A | ATCH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ATCH
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ATCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ATCH Moat Profile
Scale & Operating Efficiency Moat
Capital Markets Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ATCH vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, AtlasClear Holdings, Inc. (ATCH) is the stronger overall head-to-head candidate over aTyr Pharma, Inc. (ATYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ATCH carries a Unified Composite Score of 43.4/100 (HOLD) at $0.08 (N/M Forward P/E, -39.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ATCH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ATCH leads the Growth & Scale pillar: ATCH posts +136.8% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (71.7% gross margin, -39.4% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2026), ATCH cumulative revenue shifted +100.0% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ATCH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
ATCH screens cheaper on headline valuation multiples. ATCH trades at N/M Forward P/E, 6.6x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-15.5% EBITDA margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATCH (27.4% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, ATCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 136% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ATYR vs ATCH · Reverse Pair
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal